Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Charlene Marie Fares
Observed names:
C Fares,
C. Fares,
Charlene Fares,
Charlene M Fares,
Charlene M. Fares,
Fares, Charlene M.
show all 6
Institution:
Allina Health
Observed institutions:
Allina Health,
University of California, Los Angeles,
Ronald Reagan UCLA Medical Center,
UCLA Medical Center
ORCID:
0000-0002-7003-5917
Observed ORCID:
0000-0002-7003-5917
OpenAlex ID:
A5047786994
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
2019
·
Charlene M. Fares
, Eliezer M. Van Allen
, et al.
·
American Society of Clinical Oncology Educational Book
·
680
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
2020
·
Amy L. Cummings
, Jaklin Gukasyan
, et al.
·
Nature Cancer
·
47
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
2018
·
Charlene M. Fares
, Timothy J. Williamson
, et al.
·
JCO Clinical Cancer Informatics
·
27
Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors
2020
·
Curtis David Chin
, Charlene Marie Fares
, et al.
·
Modern Pathology
·
21
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
2021
·
Nanruoyi Zhou
, Maria A Velez
, et al.
·
Lung Cancer
·
17
Biomarkers that may predict response to immunotherapy in ovarian malignancies
2019
·
Curtis D. Chin
, Charlene M. Fares
, et al.
·
Current Opinion in Obstetrics & Gynecology
·
11
Homologous Recombination Deficiency and Molecular Subtype are Associated with Immunogenicity in Ovarian Cancer
2022
·
Charlene M Fares
, Kathleen E Fenerty
, et al.
·
Biomarkers in Medicine
·
5
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors
2026
·
Antoine Italiano
, Teresa García Manrique
, et al.
·
Frontiers in Oncology
·
4
PDF
Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
2021
·
Caroline Y. Chen
, Charlene M. Fares
, et al.
·
Journal of Medical Case Reports
·
4
PDF
Radiotherapy and local control in rectal cancer.
1998
·
V Valentini
, M E Rosetto
, et al.
·
PubMed
·
2
146 HLA-B44 motif neoepitope is associated with an anti-tumor immune microenvironment and predicts response to immune checkpoint blockade in non-small cell lung cancer
2023
·
Rui Li
, Charlene Fares
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 4340: HLA-B44 motif neoepitope is associated with a favorable tumor immune microenvironment and predicts ICB response in NSCLC
2023
·
Rui Li
, Charlene M. Fares
, et al.
·
Cancer Research
Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints.
2021
·
Kathleen Fenerty
, Charlene Marie Fares
, et al.
·
Journal of Clinical Oncology
Abstract 6614: Association between immune gene signatures and neoepitopes with electrostatic charge opposite to their HLA-B binding pocket in melanoma (MEL) and lung adenocarcinoma (LUAD)
2020
·
Charlene M. Fares
, Amy L. Cummings
, et al.
·
Cancer Research
Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism.
2020
·
Charlene Marie Fares
, Amy Lauren Cummings
, et al.
·
Journal of Clinical Oncology
Preoperative chemoradiation by infusional 5FU and bolus platinum for extraperitoneal rectal cancer: Acute toxicity, tumor response, sphincter reservation
1998
·
M.E. Rosetto
, V. Valentini
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
PDF
Show more works
View as search
Works count:
17
Citation count:
818
H-index:
6
I10-index:
6
Year
Topic
Type